• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Microchip mimics human cells for drug trials

September 19, 2016 By Sarah Faulkner

Cell-simulating chipA physics professor from the University of Texas in Dallas reportedly created a microchip that mimics human cells to study the effects of cancer-fighting drugs.

Jason Slinker, who started working on the chip in 2007 as a postdoctoral researcher, in 2010 began collaborating with David Boothman, an oncology professor at the University of Texas Southwestern Medical Center, according to the The Daily Texan.

“The idea was to design a chip that could mimic how our drug works, and define the damage that’s created, as well as, how it might be overall repaired,” Boothman said.

Slinker applies DNA to the surface of the chip, which provides the information for the device to replicate cell conditions. The researchers used betalapachone to test the device, Boothman’s anticancer drug that targets an enzyme produced in non-small-cell lung, pancreatic, breast, and other cancers.

The chip simulates the nucleus of a cell, where the DNA, membrane, and cytoplasm are located. Gold-plating along the chip conducts electrochemical signals sent from a probe inside the DNA, so the researchers can monitor the damage the drug causes to the DNA.

“Put a strand of DNA across 2 poles, just like a battery – and anytime there’s an alteration in the DNA, it gives off a signal between the 2 poles – when there’s damage created in the DNA, [Slinker] can actually see a signal by a change in the base pairs of the DNA – and then he can see when that DNA starts to be repaired,” Boothman said.

Researchers are studying betalapachone in 2 ongoing clinical trials, with 2 future trials on the way, Boothman said.

“What [Boothman] has done is really focus on cancers that don’t have effective treatments,” Slinker explained. “Anything to reduce mortality and improve the lifespan of patients would be welcomed.”

They hope the device could have applications beyond studying the effects of cancer drugs, such as detecting DNA damage due to environmental factors like radiation.

Filed Under: Drug-Device Combinations, Featured, Oncology, Research & Development Tagged With: University of Texas at Dallas, University of Texas Southwestern Medical Center

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS